Literature DB >> 8347541

Follow-up in stage I cutaneous malignant melanoma: an audit.

C A Baughan1, V L Hall, B J Leppard, P J Perkins.   

Abstract

In Southampton, follow-up of patients with malignant melanoma is carried out in a single dedicated clinic. An audit has been performed to assess its objective value in diagnosing and treating tumour relapse and its subjective value as perceived by patients. Over a 10-year period, of 331 patients with Stage I disease 65 (20%) have developed tumour recurrence. Fifty-five first relapses were either local or in regional lymph nodes, and thus potentially curable; half were found within 3 months of the previous clinic visit. Seventy-two per cent of local and 47% of nodal recurrences were either symptomatic or detected initially by the patient. Whilst doctor-diagnosed nodal recurrences tended to be smaller and to involve fewer histologically positive nodes, subsequent survival was identical in those with patient-diagnosed nodal recurrences. The clinic makes inefficient use of medical time. Questionnaire responses indicate that 54% of patients suffer anxiety prior to clinic visits. Nevertheless follow-up was considered worthwhile by 95% of patients and regular visits were preferred to a 'walk in when necessary' system. The clinic appears to have an important educational role. A series of changes to current follow-up practice are proposed including: more frequent visits for high risk patients, changes in clinic personnel, and greater emphasis on patient education and self examination.

Entities:  

Mesh:

Year:  1993        PMID: 8347541     DOI: 10.1016/s0936-6555(05)80321-8

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  9 in total

1.  Sentinel node biopsy for malignant melanoma. Having this biopsy gives psychological benefits.

Authors:  S S Rayatt; S Hettiaratchy; A Key; B W Powell
Journal:  BMJ       Date:  2000-11-18

Review 2.  Follow-up in patients with low-risk cutaneous melanoma: is it worth it?

Authors:  Ulrike Leiter; Thomas Eigentler; Claus Garbe
Journal:  Melanoma Manag       Date:  2014-12-04

Review 3.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

4.  Detection of melanoma nodal metastases; differences in detection between elderly and younger patients do not affect survival.

Authors:  S Kruijff; E Bastiaannet; A J H Suurmeijer; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2010-05-05       Impact factor: 5.344

5.  Review of diagnostic imaging modalities for the surveillance of melanoma patients.

Authors:  Yan Xing; Kate D Cromwell; Janice N Cormier
Journal:  Dermatol Res Pract       Date:  2011-08-23

6.  Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival.

Authors:  U Hofmann; M Szedlak; W Rittgen; E G Jung; D Schadendorf
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

7.  The role of ultrasound and ultrasound-guided fine needle aspiration biopsy of lymph nodes in patients with skin tumours.

Authors:  Francesco Maria Solivetti; Fulvia Elia; Maria Giulia Santaguida; Antonino Guerrisi; Paolo Visca; Maria Cecilia Cercato; Aldo Di Carlo
Journal:  Radiol Oncol       Date:  2014-01-22       Impact factor: 2.991

Review 8.  To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?

Authors:  N J Marciano; T L Merlin; T Bessen; J M Street
Journal:  Int J Clin Pract       Date:  2014-02-18       Impact factor: 2.503

9.  The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year.

Authors:  Samantha Damude; Josette E H M Hoekstra-Weebers; Anne Brecht Francken; Sylvia Ter Meulen; Esther Bastiaannet; Harald J Hoekstra
Journal:  Ann Surg Oncol       Date:  2016-05-18       Impact factor: 5.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.